<DOC>
	<DOCNO>NCT00449046</DOCNO>
	<brief_summary>This study evaluate long-term ( 24-week ) safety efficacy GW815SF Salmeterol/fluticasone propionate ( HFA MDI ) 50/100mcg ( administer 2 inhalation 25/50mcg ) bid pediatric patient bronchial asthma .</brief_summary>
	<brief_title>Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate ( HFA MDI ) In Pediatric Patients With Bronchial Asthma -A Long Term ( 24-week ) Study-</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Inclusion Criteria Entry Runin Period A pediatric patient already diagnose bronchial asthma meet follow criterion eligible study : Male female patient age ≥5 ≤14 year . Enrolment female patient childbearing potential allow test negative pregnancy test start treatment period agree undergo pregnancy test protocolspecified timing take contraceptive measure without fail study period . Written informed consent must obtain legally acceptable representative subject . Consent subject him/herself also obtain , wherever possible , give explanation easy understand possible manner . An outpatient treat ICS ( FP 100200μg/day equivalent ) least 4 week prior Visit 1 . Is suitable , investigator's/subinvestigator 's judgment , treatment GW815SF HFA MDI 25/50μg ( administer 2 inhalation 25/50μg ) bid . Able use peak flow meter correct manner investigator's/subinvestigator 's judgment . Able use MDI correct manner ( assistance his/her caregiver necessary ) investigator's/subinvestigator 's judgment . Inclusion Criteria Entry Treatment Period A subject consider eligible inclusion treatment period he/she complete runin period meet follow criterion . 1 . Has able , investigator's/subinvestigator 's judgment , make entry asthma diary measure PEF , direct , runin period . Exclusion criterion : Exclusion Criteria Entry Runin Period A patient applies follow criterion eligible study : Admitted hospital due asthma exacerbation within 8 week prior Visit 1 . Used systemic steroid within 4 week prior Visit 1 . Received antibacterial antiviral treatment upper low respiratory tract infection within 2 week prior Visit 1 . Has safety problem participation study serious , uncontrolled systemic disease include nervous system disorder . Has suspect deepseated mycosis infection effective antibacterial agent available . Has suspect hypersensitivity investigational product , rescue medication ingredient . Is pregnant lactating , may pregnant , plan pregnancy study period . Has receive last dose another clinical study within 2 month prior study . Is eligible study investigator's/subinvestigator 's judgment . Exclusion Criteria Entry Treatment Period A subject applies follow criterion eligible study : 1 . Admitted hospital due asthma exacerbation runin period . 2 . Had upper low respiratory tract infection 2 week Visit 2 . 3 . Used prohibit drug 2 week Visit 2 . 4 . Is eligible study investigator's/subinvestigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>salmeterol/fluticasone propionate combination</keyword>
	<keyword>pediatric bronchial asthma</keyword>
</DOC>